RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 3:40 PM Eastern Time. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases. RAPT has advanced drug candidates targeting C-C motif chemokine receptor 4 (CCR4) and is exploring additional targets in early development. For those interested, the presentation will be available live and archived on their website.

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 pm Eastern Time.

To access the live webcast and subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.

Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

FAQ

What will RAPT present at the J.P. Morgan Healthcare Conference?

RAPT Therapeutics will have its CEO, Brian Wong, present at the conference on January 12, 2021, discussing the company's drug development in oncology and inflammatory diseases.

When is the J.P. Morgan Healthcare Conference presentation by RAPT?

The presentation by RAPT Therapeutics is scheduled for January 12, 2021, at 3:40 PM Eastern Time.

Where can I watch RAPT's conference presentation?

You can access the live webcast and the archived presentation of RAPT Therapeutics on their official website.

What types of therapies does RAPT Therapeutics develop?

RAPT Therapeutics develops oral small molecule therapies focused on oncology and inflammatory diseases, targeting immune pathways.

What are RAPT's drug candidates?

RAPT has two main drug candidates: FLX475 and RPT193, both targeting C-C motif chemokine receptor 4 (CCR4) for cancer and inflammation treatments, respectively.